Total Voting Rights
Hemogenyx Pharmaceuticals announced on September 30, 2025, that its total issued share capital consists of 5,361,267 ordinary shares with a nominal value of 1p each. The company confirms that none of these shares are held in treasury. Therefore, the total number of voting rights attached to the company's shares is 5,361,267. This figure can be used by shareholders to calculate their notification requirements regarding their investment in the company's share capital, according to the Financial Conduct Authority's rules.
Select text to share a quote on X · sign in to keep highlights & notes in your HEMO notes
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces that the total issued share capital of the Company as at 30 September 2025 consists of 5,361,267 ordinary shares of 1p each, none of which are held in treasury. Therefore, the total number of voting rights in the Company is 5,361,267.
The figure of 5,361,267 ordinary shares may be used by shareholders of the Company as the denominator for the calculations by which they will determine if they are required to notify their investment in, or a change in their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.